Overview

A Phase 1 Trial of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With r/r DLBCL

Status:
Recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
To investigate the tolerability and safety of OPB-111077 in combination with bendamustine and rituximab in patients with r/r DLBCL.
Phase:
Phase 1
Details
Lead Sponsor:
Otsuka Pharmaceutical Co., Ltd.
Treatments:
Bendamustine Hydrochloride
Rituximab